Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Annexin A8-like protein 1 (ANXA8L1) is a member of the annexin family of Ca2+- and phospholipid-binding proteins. It is structurally related to other annexins and is anticipated to participate in Ca2+-regulated processes such as membrane repair, vesicle trafficking, and cytoskeletal organization[1][6]. ANXA8L1 may function as an anticoagulant by inhibiting the thromboplastin-specific complex, and overexpression has been associated with acute myelocytic leukemia and poor prognosis in renal cell carcinoma[3][4][6]. Although its direct biochemical and therapeutic targeting roles are unclear, the gene is implicated in cancer progression and may serve as a marker of aggressive tumor behavior[4][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Annexin A8-like protein 1 (ANXA8L1).